Codexis Achieves 100-Gram Oligonucleotide Scale-Up

Codexis has demonstrated 100-gram oligonucleotide production using its ECO Synthesis Manufacturing Platform, a scale milestone that moves enzymatic synthesis from laboratory-scale proof-of-concept into territory where CDMOs and plant heads must begin evaluating it as a credible alternative to solid-phase chemistry for siRNA manufacturing.

Data presented at the 2026 TIDES Europe annual meeting in November showed not only successful production at that scale with high product quality, but also reduced cycle time and improved process performance. Separately, stereo-defined siRNA produced via ECO Synthesis demonstrated greater potency compared with chemically synthesized material, a finding with direct implications for process development teams weighing purity and stereochemical control against throughput.

The operational roadmap sharpens the near-term picture for facilities planning. Codexis expects to begin retrofit construction of its ECO GMP Manufacturing Center in early 2027, with the facility targeted to be operational by end of 2027. The stated purpose is supply of siRNA material for preclinical investigations and Phase 1 and 2 clinical trials, positioning the platform squarely within the IND-enabling and early clinical supply chain that CDMOs and sponsor QA teams are currently mapping.

A feasibility study announced in October with an undisclosed pioneer in the siRNA field adds a concrete process development context. That partner employs a fragment synthesis and ligation strategy and is seeking purity levels above what standard solid-phase chemistry can reliably deliver, a gap Codexis is targeting with ECO Synthesis-derived stereo-defined fragments. For QA directors, the purity argument is the sharper read: if enzymatic routes can consistently outperform solid-phase on stereochemical definition, the technology enters the process validation conversation earlier than many have anticipated.

On the financial side, Codexis reported Q3 2026 total revenues of $19.3 million, up from $8.6 million in Q3 2025, with product gross margin expanding to 74.5% from 64% year-over-year. The company closed a $60 million senior secured term loan with Trinity Capital in November; the initial $42.5 million tranche refinanced existing debt held by Innovatus Life Sciences Lending Fund I, LP, with the remainder available for future drawdown. A July equity raise added approximately $25 million in net proceeds. Full-year revenue guidance was reiterated.

The GMP facility operational target of end-2027 sets a concrete checkpoint against which CDMO partnership timelines and clinical manufacturing agreements will be measured.

Source: Codexis, Inc. press release via GlobeNewswire, November 12, 2026.